Taiko Pharmaceutical Co., Ltd.

As of June 30, 2026, Taiko Pharmaceutical Co., Ltd. carries a market capitalization of 14.24B, placing it among publicly traded companies globally. Its enterprise value stands at 11.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Taiko Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Taiko Pharmaceutical Co., Ltd. has 50.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Taiko Pharmaceutical Co., Ltd. maintains a current ratio of 5.13, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Taiko Pharmaceutical Co., Ltd.'s stock has declined approximately 12.08% over the past 52 weeks. The 50-day moving average sits at 259.44, while the 200-day moving average is 276.92.

As of June 30, 2026, Taiko Pharmaceutical Co., Ltd. holds 3.17B in cash and equivalents against 235.00M in total debt, resulting in a net debt position of -2.43B. Total book value stands at 8.43B, with working capital of 5.79B providing operational flexibility.

Taiko Pharmaceutical Co., Ltd.'s most recent stock split took place on March 30, 2020 with a 1:3 split ratio.